Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.35p -4.34% 29.75p 29.50p 30.00p 31.35p 27.50p 31.25p 2,355,371 16:20:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 26.10

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
20/2/201821:52N4 Pharma - Making good drugs better.2,390
16/2/201816:22N4 Pharma76

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:20:3829.5010,0002,950.00O
16:20:3629.5010,0002,950.00O
16:13:2029.6510,1523,010.07O
16:12:5629.8416,7905,010.14O
16:01:3830.2010,0003,020.00O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
20/2/2018
08:20
N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 31.10p.
N4 Pharma has a 4 week average price of 16.50p and a 12 week average price of 7.50p.
The 1 year high share price is 35.50p while the 1 year low share price is currently 4.75p.
There are currently 87,723,751 shares in issue and the average daily traded volume is 2,037,819 shares. The market capitalisation of N4 Pharma is £26,097,815.92.
19/2/2018
13:34
parob: POTENTIAL near-term (next 3 months) share price catalysts - updated:- Nuvec point of difference study news.- Sildenefil human trials at Glasgow Royal Infirmary - update and/or results.- Further collaborations for Nuvec.- Beaufort upgrade to their share price target.- Final results (March 2018)- Aim_Chaos/Myles updated research/Nuvec modelling note.- Being tipped in the media/tipster websites.- Further holdings RNS/Institutional buying.- News on other patents.- News on other drugs being reformulated.- News on further grants.- Media coverage of any news listed above.
12/2/2018
17:20
parob: Potential near-term (next 3 months) share price catalysts:- Nuvec point of difference study news (potentially before Japan visit).- Sildenefil human trials at Glasgow Royal Infirmary - update and/or results.- Further collaborations for Nuvec.- Beaufort upgrade to their share price target.- Aim_Chaos/Myles updated research note with value attributed to Nuvec following AZ collaboration.- Being tipped in the media/tipster websites.- Further holdings RNS/Institutional buying.- News on other patents.- News on other drugs being reformulated.- News on further grants.- Media coverage of any news listed above.
07/2/2018
22:53
hughwilson: "Quote me one thing that is "negative dribble" - Delays / problems with their products - No deal announcements Bad results from either will see the share price hammered You are all deluded if you think N4P is somehow special and will be immune to a general market sell off Keep telling the punters to hold/buy so you guys can exit? Well lads, this has spoiled your fun Well there is six for you. If you think this share could be three times its share price based on one product then you have no reason to spout such negativity. I note you don`t post when the share is rising , only when you think it may be due a correction.
07/2/2018
20:41
parob: Potential near-term share price catalysts over next 3 months:- Nuvec proof of difference news (potentially before Japan visit).- Sildenefil human trials at Glasgow Royal Infirmary - update and/or results.- Beaufort upgrade on their share price target.- Further collaborations for Nuvec.- further holdings RNS?- further patents in new therapy areas.Can anyone think of anything else?
04/2/2018
08:56
jimbobaroony: After the ONZ reverse buyout, there were 71M shares in N4p. There were also 21M warrants available at 8.5p. You would assume that they will all be taken up at the current price. That makes 92M shares likely to be in circulation. Plus the addition of 5M deferred shares to NT will actually take N4P to 97M shares (rounded to nearest million). NT only gets these shares should the share price exceed 15p for ten consecutive business days within two years of admission. It has done. We should probably be using 97M shares in any calculations.
03/2/2018
08:53
nick2412: Hugh, I guess the wording translates as MedImmune / AZ have the right to discuss and seek exclusivity whilst N4P retain the right to name their price. I think it would require a very large initial milestone payment for an exclusive license, or, alternatively, necessitate buying Nuvac outright for a sum that equates in the N4P share price to pounds rather than pence for AZ (or any other company for that matter) to achieve exclusivity. The studiy highlighting the differences between Nuvac and current / other DNA /RNA drug delivery methods should be published this quarter and perhaps before the Japan visit. Existing findings suggest that Nuvac will be in demand so the potential is a)a lucrative exclusive deal with AZ b) multiple licensing deals with different partners c) a bidding war to buy Nuvac outright. Early days but it's looking interesting to say the least.
28/1/2018
17:36
hughwilson: One other point for next week. Seven days have now passed with the share price over the 15p trigger for Nigel`s deferred consideration shares. That means if the share price stays above 15p up to and including Wednesday then Nigel will receive 4,591,400 deferred consideration shares as part of the IPO. That would give him 15,935,716 shares or 18.79% of the then enlarged capital of 84,798,540 shares. In that even you can expect an RNS with regard his holding on Thursday.
15/12/2017
11:06
stephen2010: Check out ALBA. Huge multibag potential. ALBA currently trading at 0.39p target price 6p making a nice 15 bagger. Please read the following: MARKET CAP PUZZLE ❖ Alba (market cap £8.4m) is in a resources neighbourhood populated with listed companies with much enhanced market capitalisations, such as UKOG.L (£134m) and JAY.L (£172m). With either shared project interests or adjacent tenements to these companies, Alba should trade at a much higher valuation than its current token value. Like Bluejay, Alba owns 100% of its ilmenite project. Direct comparisons with UKOG are also instructive. While both companies own other projects, UKOG’s 49.9% of Horse Hill Developments Limited (HHDL), when compared to Alba’s 18.1% means that Alba has approximately one third of the value of Horse Hill compared to UKOG but only about 7% of the market capitalisation. Once the market recognises these disparities, the room for growth in Alba’s share price is undeniable. VALUATION RATIONALE - Our valuation in this First Equity Limited initiation note uses a risked valuation approach for Alba’s two main projects, at Horse Hill and TBS. The Horse Hill licences are valued using independent published technical data from Schlumberger, Xodus and Nutech on the oil potential of the licences, along with our own assumptions on recovery rates, oil discovery value, resource and development risks factors. From this a risked value of $127m net to Alba on a ‘Base Case’ basis is derived for Horse Hill. Given the similar geology and economic potential of both TBS and Dundas, we have adopted a risked closeology valuation approach, by computing an NPV for Dundas of $223m and then applying a three-tiered risked probability calculation to arrive at a value of $54.7m for TBS. Once Alba announce its JORC resource and exploration target at TBS and Bluejay its Feasibility Study results, this number is likely to be revised upwards very rapidly, possibly up to $200m, representing up to 7p per share in additional shareholder value. We compute a valuation of $185m (£139m) for Alba, equating to 6.0p per share, of which 4.1p is attributed to the stake in Horse Hill, 1.8p for TBS. Given this analysis and wealth of valuation catalysts anticipated across the project portfolio in the coming months, we recommend the shares as a ‘BUY, with a Target Price of 6.0p, representing a potential 15 times plus uplift from the current share price.
03/7/2017
17:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
18/5/2017
11:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20180220 23:49:58